tldrdailynews.com logo

Kyverna Therapeutics' IPO Surge and Cell Therapy Plans

1 min read
Source: Endpoints News
Kyverna Therapeutics' IPO Surge and Cell Therapy Plans
Photo: Endpoints News
TL;DR Summary

Kyverna Therapeutics saw its shares surge over 50% on its first day as a public biotech company after pricing at $22 and raising $319 million, following five years of development and private fundraising. CEO Peter Maag outlined plans for cell therapy in immune diseases, emphasizing the company's long journey and the support of its "Kyverna village."

Topics:business#biotech#businessfinance#cell-therapy#immune-diseases#ipo#kyverna-therapeutics
Share this article
  1. Kyverna surges after IPO, and CEO lays out plans for cell therapy in immune diseases  Endpoints News
  2. Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering  PR Newswire
  3. Kyverna’s $319M Upsized IPO Is Latest in Surge of Biotechs Going Public  BioSpace
  4. Kyverna overshoots raised IPO expectations with $319M offering  FierceBiotech
  5. Biotech Kyverna Surges 36% in Debut After Boosting IPO Size  Bloomberg

Reading Insights

Total Reads

0

Unique Readers

25

Time Saved

0 min

vs 1 min read

Condensed

56%

126 → 56 words

Want the full story? Read the original article

Read on Endpoints News